"Study Title","Study Abbreviation","Authors","Published in","Date Published","Number of Randomized Patients","Conclusion","Primary Outcome","Results for the Primary Outcome","Blinding","Comparator","Link to Article"
"
              
                Chlorthalidone vs. Hydrochlorothiazide for Hypertension-Cardiovascular Events.
              
            ","Diuretic Comparison Project Writing Group","Ishani, Areef et al.","NEJM","2022/12/14","13,523 patients","There was little difference in the occurrence of major cardiovascular outcome events or non-cancer-related deaths between patients receiving chlorthalidone and those receiving hydrochlorothiazide.","Composite of nonfatal myocardial infarction, stroke, heart failure resulting in hospitalization, urgent coronary revascularization for unstable angina, and non-cancer-related death","Hazard ratio, 1.04; 95% confidence interval, 0.94 to 1.16; P = 0.45","Not stated","Patients receiving hydrochlorothiazide vs. patients receiving chlorthalidone","https://pubmed.ncbi.nlm.nih.gov/36516076/?format=pubmed",
"
              
                Sotorasib in KRAS p.G12C-Mutated Advanced Pancreatic Cancer.
              
            ","NA","Strickler, John H et al.","NEJM","2022/12/22","38 patients","Sotorasib showed anticancer activity and had an acceptable safety profile in patients with KRAS p.G12C-mutated advanced pancreatic cancer who had received previous treatment.","Centrally confirmed objective response (defined as a complete or partial response)","8 patients had a centrally confirmed objective response (21%; 95% CI, 10 to 37)","Not stated","None","https://pubmed.ncbi.nlm.nih.gov/36546651/?format=pubmed",
"
              
                Comparison of two chemotherapy regimens in patients with newly diagnosed Ewing sarcoma (EE2012): an open-label, randomised, phase 3 trial.
              
            ","NA","Brennan, Bernadette et al.","Lancet","2022/10/29","640 patients","Error","Event-free survival","Event-free survival at 3 years was 61% with group 1 and 67% with group 2 (adjusted hazard ratio [HR] 0*71 [95% credible interval 0*55-0*92 in favour of group 1). The probability that the true HR was less than 1*0 was greater","Open-label","Group 1 (European regimen of vincristine, ifosfamide, doxorubicin, and etoposide induction, and consolidation using vincristine, actinomycin D, with ifosfamide or cyclophosphamide, or busulfan and melphalan) vs Group 2 (US regimen of vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide induction, plus ifosfamide and etoposide, and consolidation using vincristine and cyclophosphamide, or vincristine, actinomycin D, and ifosfamide, with busulfan and melphalan)","https://pubmed.ncbi.nlm.nih.gov/36522207/?format=pubmed",
"
              
                Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma.
              
            ","NA","Rohaan, Maartje W et al.","NEJM","2022/12/08","168 patients","TIL therapy was significantly more effective than ipilimumab in prolonging progression-free survival in patients with advanced melanoma.","Progression-free survival","Median progression-free survival was 7.2 months in the TIL group and 3.1 months in the ipilimumab group (hazard ratio for progression or death, 0.50; 95% CI, 0.35 to 0.72; P<0.001); 49% (95% CI, 38 to 60) and 21% (95% CI, 13 to 32) of the patients, respectively, had an objective response.","Open-label","TILs vs. ipilimumab","https://pubmed.ncbi.nlm.nih.gov/36477031/?format=pubmed",
"
              
                Q-122 as a novel, non-hormonal, oral treatment for vasomotor symptoms in women taking tamoxifen or an aromatase inhibitor after breast cancer: a phase 2, randomised, double-blind, placebo-controlled trial.
              
            ","NA","Vrselja, Amanda et al.","Lancet","2022/11/11","131","Q-122 is an effective and well tolerated non-hormonal oral treatment for vasomotor symptoms in women taking oral adjuvant endocrine therapy after breast cancer.","Difference in the mean percentage change from baseline in the Vasomotor Symptom Severity Score of moderate and severe hot flushes and night sweats (msVMS-SS) between Q-122 and placebo after 28 days of treatment","Q-122 -39% [95% CI -46 to -31] vs placebo -26% [-33 to -18]; p=0*018).","Double-blind","Q-122 (n=65) and placebo (n=66)","https://pubmed.ncbi.nlm.nih.gov/36366886/?format=pubmed",
"
              
                Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C.
              
            ","NA","Janne, Pasi A et al.","NEJM","2022/06/03","116 patients","Adagrasib showed clinical efficacy without new safety signals in patients with previously treated KRAS(G12C) -mutated NSCLC.","Objective response","48 (42.9%) had a confirmed objective response. The median duration of response was 8.5 months (95% confidence interval [CI], 6.2 to 13.8).","Blinded independent central review","KRAS(G12C) -mutated non-small-cell lung cancer (NSCLC) patients previously treated with platinum-based chemotherapy and anti-programmed death 1 or programmed death ligand 1 therapy","https://pubmed.ncbi.nlm.nih.gov/35658005/?format=pubmed",
"
              
                Prostate Cancer Screening with PSA and MRI Followed by Targeted Biopsy Only.
              
            ","GOTEBORG-2","Hugosson, Jonas et al.","NEJM","2022/12/08","37,887","MRI-directed targeted biopsy for screening and early detection in persons with elevated PSA levels reduced the risk of overdiagnosis by half at the cost of delaying detection of intermediate-risk tumors in a small proportion of patients.","Clinically insignificant prostate cancer, defined as a Gleason score of 3+3","A total of 66 of the 11,986 participants in the experimental group (0.6%) received a diagnosis of clinically insignificant prostate cancer, as compared with 72 of 5994 participants (1.2%) in the reference group, a difference of -0.7 percentage points (95% confidence interval [CI], -1.0 to -0.4; relative risk, 0.46; 95% CI, 0.33 to 0.64; P<0.001).","Not stated","Experimental group and reference group","https://pubmed.ncbi.nlm.nih.gov/36477032/?format=pubmed",
"
              
                Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial.
              
            ","NA","Hurvitz, Sara A et al.","Lancet","2022/12/10","524","Trastuzumab deruxtecan showed a significant improvement in overall survival versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer, as well as the longest reported median progression-free survival, reaffirming trastuzumab deruxtecan as the standard of care in the second-line setting.","Progression-free survival by blinded independent central review","Median progression-free survival by blinded independent central review was 28*8 months (95% CI 22*4-37*9) with trastuzumab deruxtecan and 6*8 months (5*6-8*2) with trastuzumab emtansine (hazard ratio [HR] 0*33 [95% CI 0*26-0*43]; nominal p<0*0001).","Patients and investigators were not masked to the treatment received.","Trastuzumab deruxtecan vs. Trastuzumab emtansine","https://pubmed.ncbi.nlm.nih.gov/36495879/?format=pubmed",
"
              
                Effect of Colonoscopy Screening on Risks of Colorectal Cancer and Related Death.
              
            ","NordICC Study Group","Bretthauer, Michael et al.","NEJM","2022/10/10","84,585","Screening colonoscopy may reduce the risk of colorectal cancer.","Risk of colorectal cancer and related death","Risk of colorectal cancer at 10 years was 0.98% in the invited group and 1.20% in the usual-care group, a risk reduction of 18% (risk ratio, 0.82; 95% confidence interval [CI], 0.70 to 0.93). The risk of death from colorectal cancer was 0.28% in the invited group and 0.31% in the usual-care group (risk ratio, 0.90; 95% CI, 0.64 to 1.16).","Not stated","Invited group and usual-care group","https://pubmed.ncbi.nlm.nih.gov/36214590/?format=pubmed",
